Actively Recruiting
Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Chronic Non-cancer Pain
Led by Cosima Locher · Updated on 2025-04-22
86
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
Sponsors
C
Cosima Locher
Lead Sponsor
B
Brown University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate whether the reduction of the daily morphine equivalent dose (MED) in patients with chronic non-cancer pain (CNCP) can be decreased with an open-label placebo (OLP) intervention in comparison to an electronic monitoring (EM) control group. The participants will receive the intervention (OPL or EM) over the duration of six weeks. Diverse psychological and health measures will be assessed with questionnaires over the course of the intervention. Furthermore, evaluation outcomes, qualitative outcomes and safety outcomes will be assessed. It is hypothesized that the OLP-intervention group in comparison to the EM-control group will have a significantly lower consumption of MED over the course of the study. Furthermore, this study aims to evaluate whether the OLP intervention can reduce opioid withdrawal symptoms in comparison to the control group.
CONDITIONS
Official Title
Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Chronic Non-cancer Pain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- 18 years of age or older
- German speaking
- Chronic non-cancer pain lasting 6 months or more
- Taking opioid medication orally for more than 3 months
- Motivated to reduce opioid use
- Have a primary treating physician managing opioid reduction
- Access to a computer or tablet with an email account
You will not qualify if you...
- Psychotic symptoms
- Suicidality
- Cognitive impairment affecting daily life
- Planned surgery within the next two months
- Known illegal drug or harmful alcohol use
- Allergy or intolerance to placebo pill ingredients (e.g., lactose, sucrose, corn-starch)
- Serious health problems preventing study participation
- Participation in other studies involving investigational drugs or CNCP-specific treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Zurich, Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine
Zurich, Canton of Zurich, Switzerland, 8006
Actively Recruiting
Research Team
C
Cosima Locher, PhD
CONTACT
K
Kiara Bodonyi, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here